North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

North America antibiotics market is expected to grow by 2.3% annually in the forecast period and reach USD 14.67 billion by 2030 driven by rising incidences of bacterial infection, growing awareness and need for new drugs and treatment amid the COVID-19 epidemic.

Highlighted with 26 tables and 56 figures, this 116-page report North America Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire North America antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Route of Administration, Drug Type, and Country.

Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cephalosporin

Penicillin

Macrolides

Fluoroquinolones

Quinolones

Monobactam

Aminoglycosides

Carbapenem

Other Drug Classes

Based on Action Mechanism, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cell Wall Synthesis Inhibitors

Mycolic Acid Inhibitors

RNA Synthesis Inhibitors

DNA Synthesis Inhibitors

Protein Synthesis Inhibitors

Other Mechanisms

Based on Drug Origin, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Natural Antibiotics

Semi-synthetic Antibiotics

Synthetic Antibiotics

Based on Activity Spectrum, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Broad-spectrum Antibiotics

Narrow-spectrum Antibiotics

Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Oral Administration

Intravenous Administration

Other Administration Routes

Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Brand Antibiotics

Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

U.S.

Canada

Mexico

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Route of Administration over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America antibiotics market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Table Of Content

Table Of Content

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 21

2.2 Major Growth Drivers 23

2.3 Market Restraints and Challenges 27

2.4 Emerging Opportunities and Market Trends 30

2.5 Porter's Fiver Forces Analysis 34

3 Segmentation of North America Market by Drug Class 38

3.1 Market Overview by Drug Class 38

3.2 Cephalosporin 40

3.3 Penicillin 41

3.4 Macrolides 42

3.5 Fluoroquinolones 43

3.6 Quinolones 44

3.7 Monobactam 45

3.8 Aminoglycosides 46

3.9 Carbapenem 47

3.10 Other Drug Classes 48

4 Segmentation of North America Market by Action Mechanism 49

4.1 Market Overview by Action Mechanism 49

4.2 Cell Wall Synthesis Inhibitors 51

4.3 Mycolic Acid Inhibitors 52

4.4 RNA Synthesis Inhibitors 53

4.5 DNA Synthesis Inhibitors 54

4.6 Protein Synthesis Inhibitors 55

4.7 Other Mechanisms 56

5 Segmentation of North America Market by Drug Origin 57

5.1 Market Overview by Drug Origin 57

5.2 Natural Antibiotics 59

5.3 Semi-synthetic Antibiotics 60

5.4 Synthetic Antibiotics 61

6 Segmentation of North America Market by Activity Spectrum 62

6.1 Market Overview by Activity Spectrum 62

6.2 Broad-spectrum Antibiotics 64

6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of North America Market by Route of Administration 66

7.1 Market Overview by Route of Administration 66

7.2 Oral Administration 68

7.3 Intravenous Administration 69

7.4 Other Administration Routes 70

8 Segmentation of North America Market by Drug Type 71

8.1 Market Overview by Drug Type 71

8.2 Brand Antibiotics 73

8.3 Generic Antibiotics 74

9 North America Market 2019-2030 by Country 75

9.1 Overview of North America Market 75

9.2 U.S. 78

9.3 Canada 82

9.4 Mexico 84

10 Competitive Landscape 86

10.1 Overview of Key Vendors 86

10.2 New Product Launch, Partnership, Investment, and M&A 89

10.3 Company Profiles 90

Abbott Laboratories 90

Astellas Pharma 92

AstraZeneca Plc 93

Bayer AG 94

Bristol Myers Squibb Company 95

Cipla Inc. 96

Dr. Reddy's Laboratories Ltd. 97

Eli Lilly and Company 98

F. Hoffmann-La Roche Ltd. 99

Gilead Sciences, Inc. 100

GlaxoSmithKline plc. 101

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 102

Mayne Pharma Group Ltd. 103

MELINTA THERAPEUTICS, INC. 104

Merck KGaA 105

Novartis AG 106

Pfizer Inc. 107

Sanofi 108

Sun Pharmaceutical Industries Ltd. 109

11 Investing in North America Market: Risk Assessment and Management 110

11.1 Risk Evaluation of North America Market 110

11.2 Critical Success Factors (CSFs) 113

Related Reports and Products 116


List Of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. North America Antibiotics Market, 2019-2030, USD mn 20

Figure 6. Impact of COVID-19 on Business 21

Figure 7. Primary Drivers and Impact Factors of North America Antibiotics Market 23

Figure 8. GDP per capita in the World, 1960-2018, USD thousand 26

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26

Figure 10. Primary Restraints and Impact Factors of North America Antibiotics Market 27

Figure 11. Investment Opportunity Analysis 31

Figure 12. Porter's Fiver Forces Analysis of North America Antibiotics Market 34

Figure 13. Breakdown of North America Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39

Figure 14. North America Addressable Market Cap in 2020-2030 by Drug Class, Value (USD mn) and Share (%) 39

Figure 15. North America Antibiotics Market: Cephalosporin, 2019-2030, USD mn 40

Figure 16. North America Antibiotics Market: Penicillin, 2019-2030, USD mn 41

Figure 17. North America Antibiotics Market: Macrolides, 2019-2030, USD mn 42

Figure 18. North America Antibiotics Market: Fluoroquinolones, 2019-2030, USD mn 43

Figure 19. North America Antibiotics Market: Quinolones, 2019-2030, USD mn 44

Figure 20. North America Antibiotics Market: Monobactam, 2019-2030, USD mn 45

Figure 21. North America Antibiotics Market: Aminoglycosides, 2019-2030, USD mn 46

Figure 22. North America Antibiotics Market: Carbapenem, 2019-2030, USD mn 47

Figure 23. North America Antibiotics Market: Other Drug Classes, 2019-2030, USD mn 48

Figure 24. Breakdown of North America Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50

Figure 25. North America Addressable Market Cap in 2020-2030 by Action Mechanism, Value (USD mn) and Share (%) 50

Figure 26. North America Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, USD mn 51

Figure 27. North America Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, USD mn 52

Figure 28. North America Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, USD mn 53

Figure 29. North America Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, USD mn 54

Figure 30. North America Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, USD mn 55

Figure 31. North America Antibiotics Market: Other Mechanisms, 2019-2030, USD mn 56

Figure 32. Breakdown of North America Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58

Figure 33. North America Addressable Market Cap in 2020-2030 by Drug Origin, Value (USD mn) and Share (%) 58

Figure 34. North America Antibiotics Market: Natural Antibiotics, 2019-2030, USD mn 59

Figure 35. North America Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, USD mn 60

Figure 36. North America Antibiotics Market: Synthetic Antibiotics, 2019-2030, USD mn 61

Figure 37. Breakdown of North America Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63

Figure 38. North America Addressable Market Cap in 2020-2030 by Activity Spectrum, Value (USD mn) and Share (%) 63

Figure 39. North America Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, USD mn 64

Figure 40. North America Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, USD mn 65

Figure 41. Breakdown of North America Antibiotics Market by Route of Administration, 2019-2030, % of Revenue 67

Figure 42. North America Addressable Market Cap in 2020-2030 by Route of Administration, Value (USD mn) and Share (%) 67

Figure 43. North America Antibiotics Market: Oral Administration, 2019-2030, USD mn 68

Figure 44. North America Antibiotics Market: Intravenous Administration, 2019-2030, USD mn 69

Figure 45. North America Antibiotics Market: Other Administration Routes, 2019-2030, USD mn 70

Figure 46. Breakdown of North America Antibiotics Market by Drug Type, 2019-2030, % of Revenue 71

Figure 47. North America Addressable Market Cap in 2020-2030 by Drug Type, Value (USD bn) and Share (%) 72

Figure 48. North America Antibiotics Market: Brand Antibiotics, 2019-2030, USD bn 73

Figure 49. North America Antibiotics Market: Generic Antibiotics, 2019-2030, USD bn 74

Figure 50. Breakdown of North America Antibiotics Market by Country, 2019 and 2030, % of Revenue 76

Figure 51. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value (USD bn) and Share (%) 77

Figure 52. U.S. Antibiotics Market, 2019-2030, USD bn 79

Figure 53. Rising Incidence of Infectious Disease in U.S. 79

Figure 54. Canada Antibiotics Market, 2019-2030, USD bn 82

Figure 55. Antibiotics Market in Mexico, 2015-2030, USD bn 84

Figure 56. Growth Stage of North America Antibiotics Industry over the Forecast Period 86


List Of Table

Table 1. Snapshot of North America Antibiotics Market, 2019-2030 18

Table 2. Main Product Trends and Market Opportunities in North America Antibiotics Market 30

Table 3. North America Antibiotics Market by Drug Class, 2019-2030, USD mn 38

Table 4. North America Antibiotics Market by Action Mechanism, 2019-2030, USD mn 49

Table 5. North America Antibiotics Market by Drug Origin, 2019-2030, USD mn 57

Table 6. North America Antibiotics Market by Activity Spectrum, 2019-2030, USD mn 62

Table 7. North America Antibiotics Market by Route of Administration, 2019-2030, USD mn 66

Table 8. North America Antibiotics Market by Drug Type, 2019-2030, USD bn 71

Table 9. North America Antibiotics Market by Country, 2019-2030, USD bn 76

Table 10. U.S. Antibiotics Market by Drug Class, 2019-2030, USD mn 80

Table 11. U.S. Antibiotics Market by Drug Origin, 2019-2030, USD mn 80

Table 12. U.S. Antibiotics Market by Route of Administration, 2019-2030, USD mn 80

Table 13. Canada Antibiotics Market by Drug Class, 2019-2030, USD mn 83

Table 14. Canada Antibiotics Market by Drug Origin, 2019-2030, USD mn 83

Table 15. Canada Antibiotics Market by Route of Administration, 2019-2030, USD mn 83

Table 16. Mexico Antibiotics Market by Drug Class, 2019-2030, USD mn 85

Table 17. Mexico Antibiotics Market by Drug Origin, 2019-2030, USD mn 85

Table 18. Mexico Antibiotics Market by Route of Administration, 2019-2030, USD mn 85

Table 20. Abbott Laboratories: Company Snapshot 90

Table 21. Abbott Laboratories: Business Segmentation 90

Table 22. Abbott Laboratories: Product Portfolio 91

Table 23. Abbott Laboratories: Revenue, 2016-2018, USD mn 91

Table 24. Abbott Laboratories: Recent Developments 91

Table 25. Risk Evaluation for Investing in North America Market, 2019-2030 111

Table 26. Critical Success Factors and Key Takeaways 114

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

408564 Reports in repository
150+ Consulting project
100+ Analysts
8000+ Client Queries in 2022